Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The cancelled Phase I trial that would have tested oral BPC-157 in 42 healthy volunteers never published results, leaving that data inaccessible
PubMed Cox, H.D., Smeal, S.J., Hughes, C.M., Cox, J.E., & Eichner, D
Some of the key peptides expected to be reclassified include: BPC-157: Known for its powerful healing and regenerative properties, particularly for gut health and tissue repair
the benzyl alcohol provides the bacteriostatic properties that preserve peptide solutions in multi-dose vials
Additionally, Crohns disease, celiac disease, and other intestinal issues increase the odds of developing a B12 deficiency
Staresinic et al
US$ 28.88
US$ 26.21
US$ 27.67
US$ 25.68
US$ 24.04
US$ 27.77
